A detailed history of Point72 Hong Kong LTD transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Point72 Hong Kong LTD holds 10,020 shares of RARE stock, worth $443,084. This represents 0.04% of its overall portfolio holdings.

Number of Shares
10,020
Holding current value
$443,084
% of portfolio
0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.21 - $59.36 $402,904 - $594,787
10,020 New
10,020 $556,000
Q1 2024

May 15, 2024

BUY
$43.02 - $53.69 $1.16 Million - $1.45 Million
27,004 New
27,004 $1.26 Million
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $630,009 - $1.04 Million
15,766 New
15,766 $653,000
Q1 2022

May 16, 2022

SELL
$62.2 - $84.4 $1,306 - $1,772
-21 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$73.71 - $87.86 $580,097 - $691,458
-7,870 Reduced 99.73%
21 $2,000
Q3 2021

Nov 15, 2021

SELL
$77.92 - $102.4 $172,125 - $226,201
-2,209 Reduced 21.87%
7,891 $712,000
Q2 2021

Aug 16, 2021

BUY
$92.19 - $115.71 $931,119 - $1.17 Million
10,100 New
10,100 $963,000
Q4 2020

Feb 16, 2021

SELL
$84.4 - $177.39 $58,067 - $122,044
-688 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$72.98 - $90.0 $50,210 - $61,920
688 New
688 $57,000
Q4 2019

Feb 14, 2020

SELL
$36.08 - $45.83 $721 - $916
-20 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$42.5 - $63.11 $850 - $1,262
20 New
20 $1,000
Q1 2019

May 15, 2019

SELL
$39.87 - $69.36 $917 - $1,595
-23 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$38.89 - $77.3 $1,672 - $3,323
-43 Reduced 65.15%
23 $1,000
Q3 2018

Nov 14, 2018

BUY
$71.81 - $90.15 $4,739 - $5,949
66 New
66 $5,000

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.1B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Point72 Hong Kong LTD Portfolio

Follow Point72 Hong Kong LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.